Drug Resistance Updates
Volume 9, Issue 1 , Pages 40-50 , February 2006

Tumor-specific nuclear targeting: Promises for anti-cancer therapy?

  • Gualtiero Alvisi

      Affiliations

    • Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Australia
    • ,
  • Ivan K.H. Poon

      Affiliations

    • Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Australia
    • ,
  • David A. Jans

      Affiliations

    • Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Australia
    • ARC Centre of Excellence for Biotechnology and Development, Australia
    • Corresponding Author InformationCorresponding author at: Nuclear Signalling Laboratory, Department of Biochemistry and Molecular Biology, Monash University, Wellington Road, Clayton Vic. 3168, Australia.

Received 13 January 2006 ,Revised 20 February 2006 ,Accepted 20 February 2006.

References 

  1. Akhlynina TV, Rosenkranz AA, Jans DA, Gulak PV, Serebryakova NV, Sobolev AS. The use of internalizable derivatives of chlorin E6 for increasing its photosensitizing activity. Photochem. Photobiol. 1993;58:45–48
  2. Akhlynina TV, Rosenkranz AA, Jans DA, Sobolev AS. Insulin-mediated intracellular targeting enhances the photodynamic activity of chlorin e6. Cancer Res. 1995;55:1014–1019
  3. Akhlynina TV, Jans DA, Rosenkranz AA, Statsyuk NV, Balashova IY, Toth G, et al. Nuclear targeting of chlorin e6 enhances its photosensitizing activity. J. Biol. Chem. 1997;272:20328–20331
  4. Akhlynina TV, Jans DA, Statsyuk NV, Balashova IY, Toth G, Pavo I, et al. Adenoviruses synergize with nuclear localization signals to enhance nuclear delivery and photodynamic action of internalizable conjugates containing chlorin e6. Int. J. Cancer. 1999;81:734–740
  5. Alvisi G, Jans DA, Guo J, Pinna LA, Ripalti A. A protein kinase CK2 site flanking the nuclear targeting signal enhances nuclear transport of human cytomegalovirus ppUL44. Traffic. 2005;6:1002–1013
  6. Aris A, Feliu JX, Knight A, Coutelle C, Villaverde A. Exploiting viral cell-targeting abilities in a single polypeptide, non-infectious, recombinant vehicle for integrin-mediated DNA delivery and gene expression. Biotechnol. Bioeng. 2000;68:689–696
  7. Aris A, Villaverde A. Engineering nuclear localization signals in modular protein vehicles for gene therapy. Biochem. Biophys. Res. Commun. 2003;304:625–631
  8. Bisland SK, Singh D, Gariepy J. Potentiation of chlorin e6 photodynamic activity in vitro with peptide-based intracellular vehicles. Bioconjug. Chem. 1999;10:982–992
  9. Box M, Parks DA, Knight A, Hale C, Fishman PS, Fairweather NF. A multi-domain protein system based on the HC fragment of tetanus toxin for targeting DNA to neuronal cells. J. Drug Target. 2003;11:333–343
  10. Branton PE, Roopchand DE. The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene. 2001;20:7855–7865
  11. Briggs LJ, Johnstone RW, Elliot RM, Xiao CY, Dawson M, Trapani JA, et al. Novel properties of the protein kinase CK2-site-regulated nuclear- localization sequence of the interferon-induced nuclear factor IFI 16. Biochem. J. 2001;353:69–77
  12. Brokx RD, Bisland SK, Gariepy J. Designing peptide-based scaffolds as drug delivery vehicles. J. Control. Release. 2002;78:115–123
  13. Chan CK, Hubner S, Hu W, Jans DA. Mutual exclusivity of DNA binding and nuclear localization signal recognition by the yeast transcription factor GAL4: implications for nonviral DNA delivery. Gene Ther. 1998;5:1204–1212
  14. Chan CK, Jans DA. Enhancement of polylysine-mediated transferrinfection by nuclear localization sequences: polylysine does not function as a nuclear localization sequence. Hum. Gene Ther. 1999;10:1695–1702
  15. Chan CK, Jans DA. Synergy of importin alpha recognition and DNA binding by the yeast transcriptional activator GAL4. FEBS Lett. 1999;462:221–224
  16. Chan CK, Senden T, Jans DA. Supramolecular structure and nuclear targeting efficiency determine the enhancement of transfection by modified polylysines. Gene Ther. 2000;7:1690–1697
  17. Chan CK, Jans DA. Enhancement of MSH receptor- and GAL4-mediated gene transfer by switching the nuclear import pathway. Gene Ther. 2001;8:166–171
  18. Chan CK, Jans DA. Using nuclear targeting signals to enhance non-viral gene transfer. Immunol. Cell Biol. 2002;80:119–130
  19. Chen SY, Zani C, Khouri Y, Marasco WA. Design of a genetic immunotoxin to eliminate toxin immunogenicity. Gene Ther. 1995;2:116–123
  20. Cheng CM, Huang SP, Chang YF, Chung WY, Yuo CY. The viral death protein Apoptin interacts with Hippi, the protein interactor of Huntingtin-interacting protein 1. Biochem. Biophys. Res. Commun. 2003;305:359–364
  21. Danen-van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc. Natl. Acad. Sci. U.S.A. 1997;94:5843–5847
  22. Danen-van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, et al. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J. Biol. Chem. 2003;278:27729–27736
  23. Danen-van Oorschot AA, Voskamp P, Seelen MC, van Miltenburg MH, Bolk MW, Tait SW, et al. Human death effector domain-associated factor interacts with the viral apoptosis agonist Apoptin and exerts tumor-preferential cell killing. Cell Death Differ. 2004;11:564–573
  24. De Clercq E. Antivirals and antiviral strategies. Nat. Rev. Microbiol. 2004;2:704–720
  25. Everts B, van der Poel HG. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther. 2005;12:141–161
  26. Faust RA, Niehans G, Gapany M, Hoistad D, Knapp D, Cherwitz D, et al. Subcellular immunolocalization of protein kinase CK2 in normal and carcinoma cells. Int. J. Biochem. Cell. Biol. 1999;31:941–949
  27. Fominaya J, Uherek C, Wels W. A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor. Gene Ther. 1998;5:521–530
  28. Fominaya J, Wels W. Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system. J. Biol. Chem. 1996;271:10560–10568
  29. Fontes MR, Teh T, Toth G, John A, Pavo I, Jans DA, et al. Role of flanking sequences and phosphorylation in the recognition of the simian-virus-40 large T-antigen nuclear localization sequences by importin-alpha. Biochem. J. 2003;375:339–349
  30. Fortunati E, Ehlert E, van Loo ND, Wyman C, Eble JA, Grosveld F, et al. A multi-domain protein for beta1 integrin-targeted DNA delivery. Gene Ther. 2000;7:1505–1515
  31. Fukuda M, Asano S, Nakamura T, Adachi M, Yoshida M, Yanagida M, et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature. 1997;390:308–311
  32. Gaur R, Gupta PK, Goyal A, Wels W, Singh Y. Delivery of nucleic acid into mammalian cells by anthrax toxin. Biochem. Biophys. Res. Commun. 2002;297:1121–1127
  33. Gijsens A, Missiaen L, Merlevede W, de Witte P. Epidermal growth factor-mediated targeting of chlorin e6 selectively potentiates its photodynamic activity. Cancer Res. 2000;60:2197–2202
  34. Glover DJ, Lipps HJ, Jans DA. Towards safe, non-viral therapeutic gene expression in humans. Nat. Rev. Genet. 2005;6:299–310
  35. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene. 2004;23:1153–1165
  36. Guerra B, Issinger OG. Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis. 1999;20:391–408
  37. Guillemard V, Saragovi HU. Novel approaches for targeted cancer therapy. Curr. Cancer Drug Targets. 2004;4:313–326
  38. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 2003;348:255–256
  39. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415–419
  40. Hubner S, Xiao CY, Jans DA. The protein kinase CK2 site (Ser111/112) enhances recognition of the simian virus 40 large T-antigen nuclear localization sequence by importin. J. Biol. Chem. 1997;272:17191–17195
  41. Jans DA, Ackermann MJ, Bischoff JR, Beach DH, Peters R. p34cdc2-mediated phosphorylation at T124 inhibits nuclear import of SV-40 T antigen proteins. J. Cell Biol. 1991;115:1203–1212
  42. Jori G. Tumour photosensitizers: approaches to enhance the selectivity and efficiency of photodynamic therapy. J. Photochem. Photobiol. B. 1996;36:87–93
  43. Kalderon D, Richardson WD, Markham AF, Smith AE. Sequence requirements for nuclear location of simian virus 40 large-T antigen. Nature. 1984;311:33–38
  44. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to intervention. Nat. Rev. Cancer. 2004;4:106–117
  45. Kudo N, Wolff B, Sekimoto T, Schreiner EP, Yoneda Y, Yanagida M, et al. Leptomycin B inhibition of signal-mediated nuclear export by direct binding to CRM1. Exp. Cell Res. 1998;242:540–547
  46. Lavoie JN, Nguyen M, Marcellus RC, Branton PE, Shore GC. E4orf4, a novel adenovirus death factor that induces p53-independent apoptosis by a pathway that is not inhibited by zVAD-fmk. J. Cell Biol. 1998;140:637–645
  47. Leliveld SR, Zhang YH, Rohn JL, Noteborn MH, Abrahams JP. Apoptin induces tumor-specific apoptosis as a globular multimer. J. Biol. Chem. 2003;278:9042–9051
  48. Leliveld SR, Dame RT, Mommaas MA, Koerten HK, Wyman C, Danen-van Oorschot AA, et al. Apoptin protein multimers form distinct higher-order nucleoprotein complexes with DNA. Nucleic Acids Res. 2003;31:4805–4813
  49. Leliveld SR, Dame RT, Rohn JL, Noteborn MH, Abrahams JP. Apoptin's functional N- and C-termini independently bind DNA. FEBS Lett. 2004;557:155–158
  50. Liu Q, Hamblin MR. Macrophage-targeted photodynamic therapy: scavenger receptor expression and activation state. Int. J. Immunopathol. Pharmacol. 2005;18:391–402
  51. Longshaw VM, Dirr HW, Blatch GL, Lassle M. The in vitro phosphorylation of the co-chaperone mSTI1 by cell cycle kinases substantiates a predicted casein kinase II-p34cdc2-NLS (CcN) motif. Biol. Chem. 2000;381:1133–1138
  52. Lutsenko SV, Feldman NB, Finakova GV, Posypanova GA, Severin SE, Skryabin KG, et al. Targeting phthalocyanines to tumor cells using epidermal growth factor conjugates. Tumour Biol. 1999;20:218–224
  53. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol. Lett. 2003;139:89–97
  54. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses-selective retargeting to tumor cells. Oncogene. 2005;24:7775–7791
  55. McInnis R, Perkinson RA, Kuo BA, Norton PA. Unexpected nuclear localization of a chimeric beta-galactosidase lacZ reporter gene product in mammalian cells. Biochem. Mol. Biol. Int. 1995;36:483–490
  56. Medina-Kauwe LK, Kasahara N, Kedes L. 3PO, a novel nonviral gene delivery system using engineered Ad5 penton proteins. Gene Ther. 2001;8:795–803
  57. Medina-Kauwe LK, Maguire M, Kasahara N, Kedes L. Nonviral gene delivery to human breast cancer cells by targeted Ad5 penton proteins. Gene Ther. 2001;8:1753–1761
  58. Meyer BE, Meinkoth JL, Malim MH. Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals. J. Virol. 1996;70:2350–2359
  59. Miron MJ, Gallouzi IE, Lavoie JN, Branton PE. Nuclear localization of the adenovirus E4orf4 protein is mediated through an arginine-rich motif and correlates with cell death. Oncogene. 2004;23:7458–7468
  60. Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. Gene Ther. 2000;7:548–555
  61. Noteborn MH, Todd D, Verschueren CA, de Gauw HW, Curran WL, Veldkamp S, et al. A single chicken anemia virus protein induces apoptosis. J. Virol. 1994;68:346–351
  62. Nuthall HN, Joachim K, Palaparti A, Stifani S. A role for cell cycle-regulated phosphorylation in Groucho-mediated transcriptional repression. J. Biol. Chem. 2002;277:51049–51057
  63. Oro C, Jans DA. The tumour specific pro-apoptotic factor apoptin (Vp3) from chicken anaemia virus. Curr. Drug Targets. 2004;5:179–190
  64. Paul RW, Weisser KE, Loomis A, Sloane DL, LaFoe D, Atkinson EM, et al. Gene transfer using a novel fusion protein, GAL4/invasin. Hum. Gene Ther. 1997;8:1253–1262
  65. Peng Q, Moan J, Nesland JM. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol. 1996;20:109–129
  66. Pilger BD, Perozzo R, Alber F, Wurth C, Folkers G, Scapozza L. Substrate diversity of herpes simplex virus thymidine kinase. Impact of the kinematics of the enzyme. J. Biol. Chem. 1999;274:31967–31973
  67. Poon IK, Jans DA. Regulation of nuclear transport: central role in development and transformation?. Traffic. 2005;6:173–186
  68. Poon IK, Oro C, Dias MM, Zhang J, Jans DA. Apoptin nuclear accumulation is modulated by a CRM1-recognized nuclear export signal that is active in normal but not in tumor cells. Cancer Res. 2005;65:7059–7064
  69. Poon IK, Oro C, Dias MM, Zhang JP, Jans DA. A tumor cell-specific nuclear targeting signal within chicken anemia virus VP3/apoptin. J. Virol. 2005;79:1339–1341
  70. Rainov NG, Ren H. Clinical trials with retrovirus mediated gene therapy—what have we learned?. J. Neurooncol. 2003;65:227–236
  71. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol. Genet. Metab. 2003;80:148–158
  72. Rihs HP, Jans DA, Fan H, Peters R. The rate of nuclear cytoplasmic protein transport is determined by the casein kinase II site flanking the nuclear localization sequence of the SV40 T-antigen. EMBO J. 1991;10:633–639
  73. Ritter W, Plank C, Lausier J, Rudolph C, Zink D, Reinhardt D, et al. A novel transfecting peptide comprising a tetrameric nuclear localization sequence. J. Mol. Med. 2003;81:708–717
  74. Rohn JL, Zhang YH, Aalbers RI, Otto N, Den Hertog J, Henriquez NV, et al. A tumor-specific kinase activity regulates the viral death protein Apoptin. J. Biol. Chem. 2002;277:50820–50827
  75. Rohn JL, Noteborn MH. The viral death effector Apoptin reveals tumor-specific processes. Apoptosis. 2004;9:315–322
  76. Rohn JL, Zhang YH, Leliveld SR, Danen-van Oorschot AA, Henriquez NV, Abrahams JP, et al. Relevance of apoptin's integrity for its functional behavior. J. Virol. 2005;79:1337–1338
  77. Rosenkranz AA, Lunin VG, Gulak PV, Sergienko OV, Shumiantseva MA, Voronina OL, et al. Recombinant modular transporters for cell-specific nuclear delivery of locally acting drugs enhance photosensitizer activity. FASEB J. 2003;17:1121–1123
  78. Seth P. Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem. Biophys. Res. Commun. 1994;205:1318–1324
  79. Sharman WM, Allen CM, van Lier JE. Photodynamic therapeutics: basic principles and clinical applications. Drug Discov. Today. 1999;4:507–517
  80. Silver PA, Keegan LP, Ptashine M. Amino terminus of the yeast GAL4 gene product is sufficient for nuclear localization. Proc. Natl. Acad. Sci. U.S.A. 1984;81:5951–5955
  81. Singh D, Bisland SK, Kawamura K, Gariepy J. Peptide-based intracellular shuttle able to facilitate gene transfer in mammalian cells. Bioconjug. Chem. 1999;10:745–754
  82. Sobolev AS, Jans DA, Rosenkranz AA. Targeted intracellular delivery of photosensitizers. Prog. Biophys. Mol. Biol. 2000;73:51–90
  83. Takahashi Y, Lallemand-Breitenbach V, Zhu J, de The H. PML nuclear bodies and apoptosis. Oncogene. 2004;23:2819–2824
  84. Tavassoli M, Guelen L, Luxon BA, Gaken J. Apoptin: specific killer of tumor cells?. Apoptosis. 2005;10:717–724
  85. Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K. Protein kinase CK2 signal in neoplasia. Histol. Histopathol. 2001;16:573–582
  86. Teodoro JG, Heilman DW, Parker AE, Green MR. The viral protein Apoptin associates with the anaphase-promoting complex to induce G2/M arrest and apoptosis in the absence of p53. Genes Dev. 2004;18:1952–1957
  87. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995;9:41–47
  88. Uherek C, Fominaya J, Wels W. A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery. J. Biol. Chem. 1998;273:8835–8841
  89. Vassaux G, Martin-Duque P. Use of suicide genes for cancer gene therapy: study of the different approaches. Expert Opin. Biol. Ther. 2004;4:519–530
  90. Wadia JS, Wagner MV, Ezhevsky SA, Dowdy SF. Apoptin/VP3 contains a concentration-dependent nuclear localization signal (NLS), not a tumorigenic selective NLS. J. Virol. 2004;78:6077–6078
  91. Wagstaff KM, Jans DA. Intramolecular masking of nuclear localization signals: analysis of importin binding using a novel AlphaScreen-based method. Anal. Biochem. 2006;348:49–56
  92. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 1999;5:157–163
  93. Wang QM, Fan GC, Chen JZ, Chen HP, He FC. A putative NES mediates cytoplasmic localization of Apoptin in normal cells. Acta Biochim. Biophys. Sin. (Shanghai). 2004;36:817–823
  94. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J. Natl. Cancer Inst. 2003;95:1276–1299
  95. Weis K. Importins and exportins: how to get in and out of the nucleus. Trends Biochem. Sci. 1998;23:185–189
  96. Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C, et al. Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer. 2003;97:2783–2790
  97. Williams DA, Baum C. Medicine. Gene therapy—new challenges ahead. Science. 2003;302:400–401
  98. Wilson KC, Cruikshank WW, Center DM, Zhang Y. Prointerleukin-16 contains a functional CcN motif that regulates nuclear localization. Biochemistry. 2002;41:14306–14312
  99. Xiao CY, Hubner S, Elliot RM, Caon A, Jans DA. A consensus cAMP-dependent protein kinase (PK-A) site in place of the CcN motif casein kinase II site simian virus 40 large T-antigen confers PK-A-mediated regulation of nuclear import. J. Biol. Chem. 1996;271:6451–6457
  100. Xiao CY, Hubner S, Jans DA. SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence. J. Biol. Chem. 1997;272:22191–22198
  101. Xiao CY, Jans P, Jans DA. Negative charge at the protein kinase CK2 site enhances recognition of the SV40 large T-antigen NLS by importin: effect of conformation. FEBS Lett. 1998;440:297–301
  102. Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 2006;208:299–318
  103. Zhang YH, Kooistra K, Pietersen A, Rohn JL, Noteborn MH. Activation of the tumor-specific death effector apoptin and its kinase by an N-terminal determinant of simian virus 40 large T antigen. J. Virol. 2004;78:9965–9976
  104. Zhuang SM, Landegent JE, Verschueren CA, Falkenburg JH, van Ormondt H, van der Eb AJ, et al. Apoptin, a protein encoded by chicken anemia virus, induces cell death in various human hematologic malignant cells in vitro. Leukemia. 1995;9(Suppl. 1):S118–S120

PII: S1368-7646(06)00020-3

doi: 10.1016/j.drup.2006.02.003

Drug Resistance Updates
Volume 9, Issue 1 , Pages 40-50 , February 2006

Article Tools

* Image Usage & Resolution